RGEN Repligen Corp

Price (delayed)

$215.47

Market cap

$11.34B

P/E Ratio

259.6

Dividend/share

N/A

EPS

$0.83

Enterprise value

$11.06B

Sector: Healthcare
Industry: Medical Instruments & Supplies

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights

The company's net income has surged by 87% YoY and by 42% QoQ
RGEN's EPS has surged by 63% year-on-year and by 43% since the previous quarter
The stock's P/E is 110% above its 5-year quarterly average of 123.8 and 27% above its last 4 quarters average of 203.9
RGEN's quick ratio is down by 18% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
52.62M
Market cap
$11.34B
Enterprise value
$11.06B
Valuations
Price to earnings (P/E)
259.6
Price to book (P/B)
10.06
Price to sales (P/S)
34.61
EV/EBIT
181.9
EV/EBITDA
127.91
EV/Sales
33.8
Earnings
Revenue
$327.09M
EBIT
$60.78M
EBITDA
$86.44M
Free cash flow
$43.67M
Per share
EPS
$0.83
Free cash flow per share
$0.83
Book value per share
$21.43
Revenue per share
$6.22
TBVPS
$14.82
Balance sheet
Total assets
$1.48B
Total liabilities
$351.45M
Debt
$271.78M
Equity
$1.12B
Working capital
$645.74M
Liquidity
Debt to equity
0.24
Current ratio
13.67
Quick ratio
11.95
Net debt/EBITDA
-3.26
Margins
EBITDA margin
26.4%
Gross margin
57.6%
Net margin
13.4%
Operating margin
17.8%
Efficiency
Return on assets
3.1%
Return on equity
4%
Return on invested capital
14.4%
Return on capital employed
4.3%
Return on sales
18.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
1.52%
1 week
3.41%
1 month
16.09%
1 year
116.34%
YTD
12.44%
QTD
12.44%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$327.09M
Gross profit
$188.49M
Operating income
$58.3M
Net income
$43.83M
Gross margin
57.6%
Net margin
13.4%
The company's net income has surged by 87% YoY and by 42% QoQ
The operating income has soared by 53% YoY and by 29% from the previous quarter
The net margin has grown by 44% YoY and by 31% from the previous quarter
RGEN's gross profit is up by 35% YoY and by 10% QoQ

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
P/E
259.6
P/B
10.06
P/S
34.61
EV/EBIT
181.9
EV/EBITDA
127.91
EV/Sales
33.8
The stock's P/E is 110% above its 5-year quarterly average of 123.8 and 27% above its last 4 quarters average of 203.9
RGEN's EPS has surged by 63% year-on-year and by 43% since the previous quarter
The P/B is 105% more than the 5-year quarterly average of 4.9 and 83% more than the last 4 quarters average of 5.5
Repligen's equity has increased by 8% YoY and by 2.3% QoQ
RGEN's P/S is 156% above its 5-year quarterly average of 13.5 and 75% above its last 4 quarters average of 19.8
The revenue has grown by 29% YoY and by 8% from the previous quarter

Efficiency

How efficient is Repligen business performance
RGEN's ROA is up by 41% since the previous quarter and by 35% year-on-year
The return on equity rose by 38% since the previous quarter and by 33% year-on-year
The ROIC has grown by 32% from the previous quarter but it has contracted by 25% YoY
RGEN's return on sales is up by 28% year-on-year and by 27% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
RGEN's quick ratio is down by 18% year-on-year and by 13% since the previous quarter
Repligen's current ratio has decreased by 15% YoY and by 12% QoQ
The debt is 76% less than the equity
Repligen's equity has increased by 8% YoY and by 2.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.